Although neither CAR controlled tumor outgrowth, CD19.28ζ-GLUT1 CAR-T cells mediated a significantly greater delay in tumor growth compared to CD19.28ζ CAR or MOCK+/−GLUT1 T cells (Fig. 10A), and analysis of total splenocytes at endpoint revealed a significantly higher proportion of CAR-T cells, and lower levels of residual Nalm6, in mice treated with CD19.28ζ-GLUT1 (Fig. 10B, C). This evidence concerns the gene CD19 and neoplasm.